Fundraising FoxRA Capital — 2025 Investments
24 investments dated 2025 · listed companies and verified rows first · show all
Adagio Medical Holdings develops and commercializes catheter-based ablation devices using proprietary Ultra-Low Temperature Ablation technology to treat ventricular tachycardia, a life-threatening abnormal heart rhythm, primarily in patients with structural heart disease.
HealthtechLaguna Hills, US
Todd Usen(Executive Officer, Director)inDeborah Kaster(Executive Officer)in
BoardKeyvan Mirsaeedi-Farahani(Director)Orly Mishan(Director)James L. Cox(Director)Timothy P. Moran(Director)
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses).
BiotechSan Jose, US
Talat Imran(Executive Officer, Director)inSvai Sanford(Executive Officer)inMir Hashim(Executive Officer)in
BoardAbraham Bassan(Director)Vasudev Bailey, M.D.(Director)Mir Imran(Director)
Co-investorsInCube Ventures
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsINCE CapitalSalviaBiotechnology Value FundJanus Henderson InvestorsREDMILE
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Scientific Founder)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)in
Co-investorsDroia VenturesEisai Innovation, Inc.Novartis Venture Fund
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
Co-investorsLeaps by BayerVertex Ventures HC
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US
Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in
BoardFrancesco De Rubertis(Director)in
Board seatDerek DiRocco· per SEC Form D · $57M raise · filed Jan 2025
Co-investorsMedicxiBain Capital Life SciencesLongitude Capital
Uses ML and big data to accelerate drug development.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesWaltham, US
Ajay Yekkirala, PhD(Founder)inRyan Bloom(Founder)inCATHERINE RIESEN(Executive Officer)CONY D'CRUZ(Executive Officer, Director, Promoter)inCRAIG RANDALL(Executive Officer)Ajay Yekkirala(Founder)
Board seatNandita ShangariAndrew Levin· per SEC Form D
Co-investorsGaingelsInsight PartnersNVenturesNVIDIA
__Twitter.png)
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesInkefMission BiocapitalMRL Ventures FundNextech Invest
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsLifeSci Venture PartnersBAM ElevateJanus Henderson InvestorsPatient Square Capital
Arterial automates roadway asset inventory, inspection, and condition assessment by passively collecting data from vehicles already driving a network, detecting and ranking infrastructure problems like potholes for public agencies.
AI & Machine LearningConstruction TechData & InfrastructureGovTechMobility & TransportationBoulder, US
Wade Turner(Founder)in
Co-investorsTechstarsAN Venture Partners
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsSofinnova Partners+6 more
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in
Co-investorsThird Rock VenturesSozo VenturesYosemite
Commons Clinic is an orthopedic care provider offering treatment for spine, joint, and sports medicine conditions, along with preventive health services such as full-body MRI and biomarker labs.
Digital HealthHealthtechWellness & FitnessAustin, US
Brad Hively(Director)inNick Aubin(Founder)inPaulo Marques Da Costa(Executive Officer, Director)Prithviraj Singha Roy(Director)in
BoardJohn Loser(Director)inDavid Berry(Director)in
Co-investorsCourtside VenturesFloating PointGaingelsNorth South VenturesSteelSky VenturesTime BioVentures+2 more
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedSanofi VenturesHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsHBM Healthcare InvestmentsHBM PartnersOrbiMedWestlake Village BioPartnersKleiner PerkinsNVIDIA
Evodia is a Danish aroma company that uses precision fermentation with proprietary yeast strains to produce monoterpenes, the natural molecules behind flavor and aroma, as a sustainable alternative to plant-derived ingredients.
BiotechCleantechClimate TechDeep TechFoodTechCopenhagen, DK
Co-investorsNordic Foodtech VCPINCThe March Group
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)inAlbert M. Kim(Chief Medical Officer)in
Co-investorsAN Venture PartnersCatalio Capital Management, LPSanofi VenturesSV Health InvestorsCatalio Capital Management
Reframe helps developers and builders deliver construction projects—from small multi-unit builds to community-scale developments—with more predictable timelines and outcomes.
Climate TechConstruction TechPropTechRobotics
Aaron Small(Founder)in
Co-investorsCubit CapitalEnergy Impact PartnersFoundamentalGlobal BrainService Provider CapitalVoLo Earth Ventures+2 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedSanofi VenturesSofinnova VenturesViking GlobalAgent Capital+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
NanoMosaicVaxess Technologies, Inc.Imbria PharmaceuticalsVitriVax
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.